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REVIEWThe impact of drug interactions and polypharmacy on antimicrobial
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Section of Geriatrics, University of Parma, Parma, ItalyAbstractInfectious diseases are more prevalent in older people than in younger adults, and represent a major healthcare issue in older populations. Indeed,
infections in the elderly are often associated with higher morbidity and mortality, and may present atypically. Additionally, older patients are
generally treated with polypharmacy regimens, which increase the likelihood of drug–drug interactions when the prescription of an
antimicrobial agent is needed. A progressive impairment in the functional reserve of multiple organs may affect either pharmacokinetics or
pharmacodynamics during aging. Changes in body composition occurring with advancing age, reduced liver mass and perfusion, and reduced
renal excretion may affect either pharmacokinetics or pharmacodynamics. These issues need to be taken into account when prescribing
antimicrobial agents to older complex patients taking multiple drugs. Interventions aimed at improving the appropriateness and safety of
antimicrobial prescriptions have been proposed. Educational interventions targeting physicians may improve antimicrobial prescriptions.
Antimicrobial stewardship programmes have been found to reduce the length of hospital stay and improve safety in hospitalized patients, and
their use in long-term care facilities is worth testing. Computerized prescription and decision support systems, as well as interventions aimed
at improving antimicrobial agents dosage in relation to kidney function, may also help to reduce the burden of interactions and inherent costs.
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is often a challenging issue. Indeed, the type of antibiotic should
take into account factors related to patient, culprit pathogen (if
and when possible), pharmacokinetic and pharmacodynamic
properties, as well as the presence of polypharmacy with the
inherent risk of adverse drug reactions, or drug–drug or
drug–disease interactions.Microbiol Infect 2015; 21: 20–26
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.09.011The aim of this review is to describe the changes in phar-
macokinetics and pharmacodynamics occurring during aging, as
well as their impact on polypharmacy and drug interactions
involving antimicrobial agents. We focus on clinically relevant
interactions with non-antimicrobial medications frequently
used in older patients. Potentially useful interventions for
reducing the risk of drug interactions when prescribing anti-
microbials to older patients are also reviewed.Age-related changes in pharmacokinetics
and pharmacodynamicsAging is generally characterized by changes in all phases of
pharmacokinetic processes (Table 1). However, changes in
pharmacokinetics may also result from the co-administration ofious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Age-related changes in pharmacokinetics relevant to interactions involving antimicrobial agents
Age related changes Potential impact on interactions
Absorption Increased gastric pH Increased risk of drug-induced oesophageal lesions
Delayed gastric emptying Changes in solubility and chemical stability of drugs
Reduced splanchnic blood ﬂow Changes in tmax and Cmax
Decreased absorption surface Reduced active transport
Decreased gastrointestinal motility
Distribution Changes in body composition Increased volume of distribution for lipo-soluble drugs
Reduced protein-binding sites Reduced volume of distribution for water-soluble drugs
Changes in blood–brain barrier permeability (conﬂicting evidence) Increased toxicity from selected drugs in the presence of severe hypoalbuminaemia
Increased bioavailability of drugs displaced from protein-binding sites
Metabolism Reduced hepatic blood ﬂow and overall liver mass Inhibition and/or induction of cytochrome P450s in the context of polypharmacy regimens
Less effective ﬁrst-pass metabolism and phase I metabolism
Reduced cytochrome P450 activity (conﬂicting evidence)
Excretion Reduced kidney glomerular ﬁltration rate and tubular secretion Impaired elimination of water-soluble drugs
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leading to clinically relevant interactions.
Absorption
Reduced oesophageal peristalsis and gastric acid secretion [1]
usually have only a minor impact on oral antibiotic absorp-
tion. However, an excess increase in gastric pH, as can be
produced by long-term use of proton pump inhibitors, can alter
solubility and chemical stability of β-lactams, macrolides and
azoles, reducing their bioavailability [2]. Age-related reduced
gastric emptying and peristalsis [3,4], splanchnic blood ﬂow and
bowel surface area [5] can reduce the bioavailability of amox-
icillin and clavulanic acid when assumed following the meal [6].
Reduced active transport function may also lead to clinically
important drug interactions, which are of particular importance
in older patients treated with complex polypharmacy regimens
[7,8]. Macrolides may increase serum concentrations of calcium
channel blockers and sulphonylureas by inhibiting intestinal
cytochrome P450 3A4 (CYP3A4), and cause digoxin toxicity by
inhibiting intestinal P-gp [9]. The inhibition of intestinal CYP3A4
by macrolides may increase the risk of toxicity from several
drugs, including midazolam, cyclosporine, statins, anti-
arrhythmics, tricyclic antidepressants, antipsychotics and
warfarin. Finally, speciﬁc antifungal agents, such as itraconazole
and caspofungin, can also inhibit CYP3A4 and P-gp [9].
Distribution
Overall, the volume of distribution for lipophilic drugs may
increase with a prolonged half-life [10], whereas water-soluble
drugs may have a smaller volume of distribution causing a more
rapid increase in plasma concentrations [11], and indicating the
need for lower initial doses [12]. Age-related changes in plasma
protein binding seem to be less important for drug therapy, as
steady-state unbound drug concentration often redistributes
and remains unaltered [9,13]. More pronounced changes in
protein-binding capacity are generally due to disease-related
hypoalbuminaemia [14]. A recent retrospective observationalClinical Microbiology and Infection © 2014 European Society of Clinical Microbiolostudy of 94 older patients with methicillin-resistant Staphylo-
coccus aureus hospital-acquired pneumonia showed that patients
with severe hypoalbuminaemia had signiﬁcantly longer vanco-
mycin half-life (33.2 + 5.4 versus 24.9 + 1.6; p 0.049), greater
risk of 28-day mortality in relation to high values of the area
under the concentration curve (AUC)/minimum inhibitory
concentration (MIC) (250–450 or >450 μg × h/mL), and more
frequent nephrotoxicity (26% versus 8%, p <0.001) compared
with patients with mild hypoalbuminaemia [15]. Hence, severe
hypoalbuminaemia needs to be addressed when vancomycin is
prescribed to older patients.
Protein-binding drug interactions involving antimicrobial
agents also deserve mentioning: co-trimoxazole is known to
increase serum concentrations of methotrexate and sulpho-
nylureas by displacing them from plasma protein-binding sites,
resulting in a clinically relevant increased risk of hypoglycaemia
and severe bone marrow depression [9], respectively.
Metabolism
The bioavailability of drugs undergoing extensive ﬁrst-pass
metabolism increases [16,17], while the bioavailability of
drugs that need to be activated in the liver is reduced [18]. In
elderly patients, the hepatic clearance of drugs undergoing ﬂow-
limited metabolism may be reduced up to 40% [19,20]. Hepatic
clearance by cytochrome P450 (CYP) -mediated phase I oxi-
dization, reduction and hydrolysis reactions is impaired to a
greater extent with respect to clearance mediated by phase II
conjugation reactions, mainly because of the reduced hepatic
blood ﬂow and overall liver size [19,20]. The effects of aging on
the CYP activities are still a matter of debate [21–23]. An age-
related 20% reduction in the metabolism of CYP2D6 substrates
has been observed [24,25]. Such a ﬁnding has not been
conﬁrmed for the CYP3A subfamily, which is responsible for
the elimination of more than 50% of its substrates [26–28].
Additionally, the activation of some important CYPs, including
CYP3A4, CYP2D6 and CYP1A2, does not seem to change with
aging [29,30].gy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 20–26
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roquinolones and antifungal azole derivatives undergo meta-
bolic processes in the liver, consisting of phase I metabolism
(oxidation) followed by phase II (conjugation) to make drugs
hydro-soluble leading to their renal excretion [2,31]. Macro-
lides, with the exception of azithromycin, inhibit the CYP3A4,
and the risk of interaction is greatest with orally administered
substrates, such as erythromycin, clarithromycin and teli-
thromycin, which can inhibit both intestinal and hepatic
CYP3A4 [9,32,33]. Increased concentrations of selected
CYP3A4 substrates, such as midazolam, cyclosporine, tacroli-
mus, lovastatin, simvastatin and calcium-channel blockers, may
have clinically relevant harmful effects, including excessive
sedation and falls from benzodiazepines, nephrotoxicity from
immunosuppressive agents, rhabdomyolysis from statins, and
hypotension from antihypertensive drugs [9,34,35]. Erythro-
mycin and, to a lesser extent, clarithromycin and telithromycin
may prolong prothrombin time in patients on warfarin
[9,32,33], with consequent increased risk of haemorrhagic
events. Enhanced toxicity of phenytoin, sulphonylureas and
theophylline has been reported with concomitant use of mac-
rolides [9,32,33,36]. Finally, the inhibition of CYP3A4 by mac-
rolides may also cause fatal drug interactions, such as QTc
prolongation leading to torsade de pointe and death due to an
increase in levels of some anti-arrhythmics, tricyclic antide-
pressants and antipsychotic agents [9]. Additionally, by inhibit-
ing CYP3A4, macrolides may increase circulating
concentrations of donepezil, a cholinesterase inhibitor used in
dementia patients, causing an enhancement in vagal neuro-
transmission and severe alterations in the sinus node and car-
diac conduction systems, sinus bradycardia, neurocardiogenic
syncope and bradyarrhythmias [37,38]. Although a recent study
failed to ﬁnd a signiﬁcantly increased risk of cardiac adverse
events in older people on donepezil who were concomitantly
exposed to clarithromycin, antimicrobial drugs other than
clarithromycin should be preferred whenever possible [39].
Azithromycin lacks the appreciable drug–drug interactions
seen with other macrolide antibiotics and is considered the
safest of all macrolides from a cardiac perspective. However,
the recent ﬁnding of a small increase in risk of cardiac events in
older patients with pneumonia treated with azithromycin de-
serves further investigation [40].
By inhibiting CYP3A4 and CYP1A2, ﬂuoroquinolones may
enhance the toxicity of selected drugs largely used in older
patients, such as benzodiazepines, fentanyl, carbamazepine,
statins, theophylline, haloperidol and warfarin. On the contrary,
rifampin reduces the bioavailability of warfarin, phenytoin, val-
proic acid, caspofungin, azoles, digoxin, amiodarone, statins,
β-blockers and sulphonylureas by inducing CYP2C9, CYP2C19
and CYP3A4 [9].Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectExcretion
Renal excretion of drugs can signiﬁcantly change during
advancing age, increasing the risk of toxicity from kidney-
cleared antimicrobials. Additionally, several renal excretion in-
teractions involve antimicrobial agents. Plasma concentrations
of β-lactams can be increased by drugs affecting their renal
tubular secretion, such as probenecid, methotrexate, aspirin
and indomethacin. In particular, the co-administration of pro-
benecid doubles the AUCs of amoxicillin, ampicillin, ticarcillin
and nafcillin, and increases by 55% the AUC of meropenem [9].
Although higher concentrations of these agents may be desir-
able for the management of meningitis and endocarditis, the use
of probenecid to boost β-lactam concentrations should be
avoided in older patients, as well as in those with renal
dysfunction, or a history of seizure due to the increased risk of
antibiotic-induced convulsions [9,41]. Reduced tubular secre-
tion is also the interaction mechanism by which amantadine,
digoxin and methotrexate may increase serum concentration
and enhance toxicity of co-trimoxazole [9]. Finally, ciproﬂox-
acin may reduce renal excretion and tubular secretion of
methotrexate, leading to severe dermatological, bone marrow,
hepatic and renal toxicity [9,42].
Pharmacokinetics/pharmacodynamics
With regards to antimicrobial agents, pharmacodynamics re-
ﬂects the relationship between serum concentration and the
extent to which the drug is able to bind or interact with its
speciﬁc bacterial target causing cell growth inhibition or death,
as measured by MIC [43,44]. Overall, antimicrobial agents may
have either a concentration-dependent (e.g. aminoglycosides
and quinolones) or a time-dependent (e.g. β-lactams, vanco-
mycin and clindamycin) killing activity. The pharmacodynamic
response of concentration-dependent antibiotics largely de-
pends on the maximum plasma level reached. Conversely, the
killing activity of time-dependent antibiotics depends on the
amount of time during which the plasma antibiotic concentra-
tion exceeds the MIC for the organism. For this reason, these
agents are optimized by providing smaller, frequent doses or
continuous infusion [43–45]. The above considerations clearly
indicate that it is very difﬁcult to separate pharmacodynamic
processes from pharmacokinetics, and that both age-related
changes in pharmacokinetics and pharmacokinetic interactions
may obviously affect pharmacodynamics. Indeed, the pharma-
cokinetics/pharmacodynamics ratio predicts the therapeutic
response of microorganisms to antimicrobials by correlating
free drug (f ) exposure (area under the plasma concentra-
tion–time curve over 24 h of dosing (fAUC24)) to measures of
drug potency (MIC). Hence, the pharmacokinetics/pharmaco-
dynamics parameters able to predict clinical outcomes are the
fCmax/MIC, the fAUC0–24/MIC (i.e. the area under theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 20–26
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time above the MIC (T/MIC) [43]. Using pharmacokinetics/
pharmacodynamics parameters for dosing antimicrobials may
be useful to achieve therapeutic goals, prevent selection of
drug-resistant bacteria and minimize toxic effects when treating
infections in older patients [44].
The impact of polypharmacy and
interventions to reduce risksOlder patients with co-morbid conditions are frequently
excluded from clinical trials [46], and evidence coming from
these studies is only partly applicable to this population. This
bias also affects clinical practice guidelines that are based on
evidence coming from randomized trials and meta-analyses
[47]. Guidelines are generally disease-focused, which raises
difﬁculties when applying them in older patients with co-morbid
conditions. Indeed, a guideline-driven therapeutic approach in
such patients often results in adverse drug–drug or drug–dis-
ease interactions in the presence of complex polypharmacy
regimens [48].
The risk of potentially dangerous pharmacological in-
teractions involving antimicrobial agents is among the most
frequent and undesirable consequences of polypharmacy in
older persons. The use of antimicrobial agents in a complex
multi-drug regimens was found to be a greater independent risk
factor for adverse drug events compared with other drug
classes, including antipsychotics or antidepressants, in older
nursing home residents [49]. For this reason, lists of clinically
important drug interactions, some of which are speciﬁc to the
elderly [50,51], and recommendations have been proposed
[52,53]. Unfortunately, drug interactions are not easily pre-
dictable, and nor are variations in speciﬁc drug metabolism. It is
important to optimize outcomes and to avoid harm fromTABLE 2. Summary of evidence about interventions speciﬁcally aim
prescriptions
Study Setting and intervention
Lutters et al. [54] Geriatric hospital
Educational intervention targeting prescribing physicians
Liew et al. [55] Hospital
Antimicrobial stewardship programs
Gonzales et al. [56] Medicare ofﬁce visits
Educational intervention targeting patients and caregivers
Bedouch et al. [57] Hospital, medical wards
Computerized physician order entry system and pharmacists
Rivkin et al. [58] Intensive care unit
Interactions screening procedure guided by clinical pharmacist
Buising et al. [59] Emergency department
Computerized decision support system
Joosten et al. [60] Ambulatory care setting
Automatic renal function alerts (involving general practitioners and
community pharmacists)
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiolopotentially dangerous interactions by implementing guiding
principles for antimicrobial use in older adults. These aims
should include the following [52].
 Stratify patient risks for severe infections and multidrug-
resistant pathogens based on lifestyle and functional status.
 Provide early empiric therapy using national guidelines and
local antibiogram when available.
 Obtain complete medication history and carefully select
antimicrobials to avoid interactions.
 Correctly reach maximal therapeutic doses of antimicrobials
according to age-related changes in pharmacokinetics and
pharmacodynamics to avoid potential adverse effects.
 Discontinue antimicrobial therapy based on the patient’s
clinical status and identiﬁed pathogen.
 Perform clinical trials testing the use of antimicrobial agents
in older populations.
Interventions aimed at improving the appropriateness and
safety of antimicrobial prescriptions have been investigated
(Table 2) [54–61].
Educational interventions targeting prescribing physicians
were found to improve antibiotic prescribing practice and to
signiﬁcantly reduce consumption and costs of antibiotics in a
geriatric hospital [54].
Antimicrobial stewardship programmes (ASPs), deﬁned as
the coordinated effort to optimize antimicrobial usage (the
right agent, at the right time, at the correct dose, for an
appropriate duration) with the goals of improving patient out-
comes, reducing antimicrobial resistance and decreasing
healthcare costs [61], have been found to reduce the length of
hospital stay and improve safety in hospitalized patients [55].
ASP interventions have also been investigated in long-term care
facilities, where residents are often colonized with multidrug-
resistant organisms and treated for inappropriately longed at improving appropriateness and safety of antimicrobial
Evidence
Reduced consumption and costs of antibiotics
Reduce length of hospital stay and improved safety
Modest decline in antibiotic use for acute respiratory infections, but no substantial
effect
Routine participation of clinical pharmacists in clinical medical rounds may facilitate
identiﬁcation of drug-related problems and enhance patient safety
Decreased number of clinically important interactions requiring therapy
modiﬁcation, and reduced length of stay
Improved antibiotic prescribing practices
A considerable proportion of the population is at risk for adverse drug events from
antimicrobials due to impaired renal function
Providing pharmacists and physicians with renal function data may help them to
adjust medication dosage
gy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 20–26
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costs and resistance associated with antibiotic overuse [62].
Although the efﬁcacy of ASPs and how they ﬁt into individual
facility types with differing resources still need to be investi-
gated [63], a 30% decrease in systemic antibiotic usage, as well
as a decrease in the rate of C. difﬁcile infections, has been
observed with ASP in a preliminary single-centre study of long-
term care facility residents [64].
Computerized support systems have been proved to be
effective in identifying antimicrobial-related problems, and
increasing the rate of appropriate prescriptions when a clin-
ical pharmacist is involved [57,58]. A computerized decision
support system improved the rate of appropriate empirical
antibiotic treatment while reducing antibiotic costs and the
use of broad-spectrum antibiotic treatment in the context of
a cluster randomized controlled trial [65]. Additionally,
computerized support system interventions led to a signiﬁ-
cant improvement in antibiotic prescribing practices in pa-
tients presenting to the emergency department with
community-acquired pneumonia, and appropriateness of
prescriptions was greater than that obtained with academic
detailing [59]. Nevertheless, barriers to electronic antibiotic
prescribing are still a relevant concern to be addressed to
leverage the potential that computerized decision-support
systems offer in reducing costs, improving quality and
improving patient safety [66].
Interventions to improve antimicrobial selection and dosing
in relation to kidney function deserve particular attention.
Despite the importance of dosage adjustment among patients
with renal impairment, such adjustments are rarely made
[67,68]. Indeed, non-compliance with dosing guidelines in
hospitalized patients with chronic kidney disease ranges from
19% to 67% [69]. Evidence suggests that reporting estimated
glomerular ﬁltration rate (eGFR) may not signiﬁcantly change
prescription habits for nephrotoxic medications, including
antibiotics [70,71]. Recently, Joosten et al. [60] showed that
introducing automatic renal function alerts in the ambulatory
care setting, with the involvement of both general practi-
tioners and community pharmacists, was able to reveal that a
considerable proportion of the population is at risk for
adverse drug events due to impaired renal function. This type
of study provided renal function data to the pharmacists to
indicate medication dosage adjustments with prescribing phy-
sicians [60]. Hence, it is likely that strategies to implement
dosage adjustment in relation to renal function could beneﬁt
from the involvement of other professionals involved in the
care process, as well as from technology. Indeed, computer-
ized software programs for medication adjustments may
improve the appropriateness of prescribed medications and
doses [68].Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectConclusionsMultiple chronic diseases and complex polypharmacy regimens
makes the choice of the right antimicrobial agent very challenging
when an infection occurs in older patients. Age-related pharma-
cokinetic changes play a key role in the risk of drug interactions in
these patients [72]. Selected interventions, such as educational
interventions, antimicrobial stewardship, computerized pre-
scription and decision support systems, and interventions aimed
at improving drug dosage in relation to kidney function, proved to
be effective in improving appropriateness and safety when pre-
scribing antimicrobial agents. Hence, the ability of physicians to
prescribe safer and more effective antimicrobial therapies when
visiting older people with multiple chronic diseases depends
substantially on how theywill be able to incorporate the principles
of drug pharmacokinetics and pharmacodynamics into daily clin-
ical practice [73], as well as how interventions speciﬁcally aimed at
improving the quality of antimicrobial prescriptions will be
implemented in clinical practice.Transparency DeclarationConﬂict of interest disclosure: The authors declare that they
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